---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-24-000142"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:12:00.585415+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions Q2 revenue $254.7M, net loss $283.1M; updates FY2024 guidance

## Summary
- Q2 revenue $254.7M (above guidance); net loss $283.1M ($5.38/diluted), adjusted EBITDA -$10.1M.
- Bioservices services revenue $64.5M (+144% YoY) including $50M Janssen arbitration settlement; cost $211.6M with asset write-down.
- Updated FY2024: total revenue $1,050-$1,125M (raised); net loss $(314)-$(274)M (wider); adj. EBITDA $140-$180M (raised).
- Asset sales: $30M Baltimore-Camden site sale expected Q3 2024; $75M from RSDL sale to SERB; $50M Janssen dispute resolution.
- Impairment $27.2M in Q2 vs $306.7M a year ago, related to Bayview and Rockville asset groups.

## SEC filing metadata
- accession: 0001367644-24-000142
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000142/0001367644-24-000142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000142/ebs-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-24-000142
- JSON: https://secwatch.observer/filing/0001367644-24-000142.json
- Plain text: https://secwatch.observer/filing/0001367644-24-000142.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.